Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Dose Escalation, Efficacy, and Safety Study of CLR 131 in Children, Adolescents, and Young Adults With Select Solid Tumors, Lymphoma, and Malignant Brain Tumors

NCT03478462 is registered in ClinicalTrials.gov with Cellectar Biosciences, Inc. as lead sponsor.

NCT NCT03478462
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03478462 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Dose Escalation, Efficacy, and Safety Study of CLR 131 in Children, Adolescents, and Young Adults With Select Solid Tumors, Lymphoma, and Malignant Brain Tumors
Lead sponsor
Cellectar Biosciences, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 30, 2019
Completion date
December 31, 2027
Enrollment
30 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

dipg, ewing sarcoma, neuroblastoma, osteosarcoma, pediatric brain tumor, pediatric lymphoma, pediatric solid tumor, rhabdomyosarcoma